🔗 Share this article

As the US undertakes sweeping adjustments to its vaccine guidelines, a particular individual appears unexpectedly: Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines during the global health crisis and has focused upon potential deaths after COVID-19 immunization in her brief position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders planned to announce major revisions to the pediatric vaccination calendar recently, bringing the US with the Danish national calendar, sources say – a substantial departure that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Qualifications

Høeg has no obvious track record in drug development, oversight or leadership, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for running the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Past heads of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who headed the center have had.”

This division has an immense workload at the agency, she emphasized.

“The public just pays attention on the novel medication approvals, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and other areas, and all of those have to be managed,” she said. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major management aspect to the role, which oversees more than 5,000 staff members. “It is a huge administrative position, if you do it right,” she added.

Agency Reaction and Contentious Initiatives

When asked about concerns about Høeg’s credentials and whether this assignment signifies more teamwork among FDA leaders on vaccines, a spokesperson said that the “concerns rely on flawed assumptions”.

“This background aligns with the functions of her job,” the spokesperson stated, noting the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a controversial rapid drug-approval program that apparently worried her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who takes the decisions?” Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, aside from shots.”

Public Past Work on Vaccines

With immunizations, Høeg has a more documented, if troubling, history, Howard have noted. She released a study using non-validated public submissions to determine the frequency of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the new administration featured changing guidelines for novel immunizations and halting “non-essential” vaccines, she remarked after the election on a online show. At the agency, Høeg has according to sources suggested preventing adolescent males from receiving Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to accommodate the data in a very deceptive, fraudulent way,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow skeptics, {like|